Search bioRxiv⌕ Search

Biology subjects

K C, S.

Publications and source records attributed to K C, S..

2 recordsLinked to original sources

ESAT-6 of Mycobacterium tuberculosis downregulates cofilin1 and reduces the phagosome acidification in infected macrophages

Mycobacterium tuberculosis when phagocytosed by macrophages is not cleared completely and many of the bacteria remain in phagosomes indefinitely. In this study we considered abnormal retention of filamentous actin on early phagosomes contributing to defective phagosome acidification. The actin depolymerizing protein cofilin1 was found downregulated in macrophages infected with virulent M. tuberculosis. Also, phosphocofilin1, the inactive form of cofilin1, which leads to retention of filamentous actin, and the total filamentous actin itself were found upregulated in macrophages infected with virulent M. tuberculosis. Over expression of constitutively active cofilin1 in macrophages was found to decrease the level of filamentous actin and increase phagosome acidification when infected with virulent M. tuberculosis. The anticancer drug sorafenib which activates cofilin1 in PI3K dependent manner was also found to decrease the filamentous actin level and increase phagosome acidification. Cofilin1, known to be positively regulated by superoxide was found to be downregulated by ESAT-6 of M. tuberculosis where the latter is known to reduce ROS in macrophages. Ectopic expression of ESAT-6 in macrophages was found to downregulate cofilin1, increase filamentous actin and to transform the macrophages more spindle shaped. ESAT-6 was also found to decrease phagosome acidification in macrophages infected with an avirulent M. tuberculosis strain. Finally, this study proposes a role for the amino acid methionine in resisting ROS by creating M93 mutants of ESAT-6.

immunology↗

Acetylation of isoniazid - a novel mechanism of isoniazid resistance in Mycobacterium tuberculosis

Isoniazid (INH), one of the first-line drugs used for the treatment of tuberculosis, is a pro-drug which is converted into its active form by the intracellular KatG enzyme of Mycobacterium tuberculosis. The activated drug hinders cell wall biosynthesis by inhibiting InhA protein. INH resistant strains of M. tuberculosis usually have mutations in katG, inhA, ahpC, kasA, and ndh genes. However, INH resistant strains which do not have mutations in any of these genes are reported, suggesting that these strains may adopt some other mechanism to become resistant to INH. In the present study we characterized Rv2170, a putative acetyltransferase in M. tuberculosis, to elucidate its role in inactivating isoniazid. The purified recombinant protein was able to catalyze transfer of acetyl group to INH from acetyl CoA. HPLC and LC-MS analyses showed that following acetylation by Rv2170, INH is broken down into isonicotinic acid and acetylhydrazine. Drug susceptibility assay and confocal analysis showed that M. smegmatis, which is susceptible to INH, is not inhibited by INH acetylated with Rv2170. Recombinant M. smegmatis and M. tuberculosis H37Ra overexpressing Rv2170 were found to be resistant to INH at minimum inhibitory concentrations that inhibited wildtype strains. In addition, intracellular M. tuberculosis H37Ra overexpressing Rv2170 survived better in macrophages when treated with INH. Our results strongly indicate that Rv2170 acetylates INH, and this could be one of the strategies adopted by at least some M. tuberculosis strains to overcome INH toxicity.

biochemistry↗